TANGO THERAPEUTICS INC (TNGX) Stock Price, Quote, News and Overview
NASDAQ:TNGX - Nasdaq - US87583X1090 - Common Stock - Currency: USD
TNGX Quote, Performance and Key Statistics
1.1
-0.05 (-4.35%)
The current stock price of TNGX is 1.1 USD. In the past month the price decreased by -21.99%. In the past year, price decreased by -84.52%.
TNGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 328.29B | ||
| AMGN | AMGEN INC | 13.1 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 12.68 | 122.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.13B | ||
| ARGX | ARGENX SE - ADR | 96.95 | 34.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.61B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.78B | ||
| NTRA | NATERA INC | N/A | 22.10B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.31B | ||
| BIIB | BIOGEN INC | 7.48 | 17.35B |
Related stock screener links
About TNGX
Company Profile
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Company Info
TANGO THERAPEUTICS INC
201 Brookline Avenue, Suite 901
Boston MASSACHUSETTS US
CEO: Aaron I. Davis
Employees: 155
Phone: 18573204900
TANGO THERAPEUTICS INC / TNGX FAQ
What is the stock price of TANGO THERAPEUTICS INC today?
The current stock price of TNGX is 1.1 USD. The price decreased by -4.35% in the last trading session.
What is the ticker symbol for TANGO THERAPEUTICS INC stock?
The exchange symbol of TANGO THERAPEUTICS INC is TNGX and it is listed on the Nasdaq exchange.
On which exchange is TNGX stock listed?
TNGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TANGO THERAPEUTICS INC stock?
14 analysts have analysed TNGX and the average price target is 11.22 USD. This implies a price increase of 920% is expected in the next year compared to the current price of 1.1. Check the TANGO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TANGO THERAPEUTICS INC worth?
TANGO THERAPEUTICS INC (TNGX) has a market capitalization of 118.92M USD. This makes TNGX a Micro Cap stock.
How many employees does TANGO THERAPEUTICS INC have?
TANGO THERAPEUTICS INC (TNGX) currently has 155 employees.
What are the support and resistance levels for TANGO THERAPEUTICS INC (TNGX) stock?
TANGO THERAPEUTICS INC (TNGX) has a resistance level at 1.27. Check the full technical report for a detailed analysis of TNGX support and resistance levels.
Is TANGO THERAPEUTICS INC (TNGX) expected to grow?
The Revenue of TANGO THERAPEUTICS INC (TNGX) is expected to decline by -36.08% in the next year. Check the estimates tab for more information on the TNGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TANGO THERAPEUTICS INC (TNGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TNGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TNGX, evaluating the profitability, health, valuation and growth aspects
- TANGO THERAPEUTICS INC (TNGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TANGO THERAPEUTICS INC (TNGX) Sales and EPS estimates to see what analysts future expectations are.
- TANGO THERAPEUTICS INC (TNGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TANGO THERAPEUTICS INC (TNGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TANGO THERAPEUTICS INC (TNGX) Stock Chart to make your own analysis
- TANGO THERAPEUTICS INC (TNGX) Latest news and press-releases to stay up to date.
Does TANGO THERAPEUTICS INC (TNGX) stock pay dividends?
TNGX does not pay a dividend.
When does TANGO THERAPEUTICS INC (TNGX) report earnings?
TANGO THERAPEUTICS INC (TNGX) will report earnings on 2025-05-12, before the market open.
What is the Price/Earnings (PE) ratio of TANGO THERAPEUTICS INC (TNGX)?
TANGO THERAPEUTICS INC (TNGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
What is the Short Interest ratio of TANGO THERAPEUTICS INC (TNGX) stock?
The outstanding short interest for TANGO THERAPEUTICS INC (TNGX) is 11.43% of its float. Check the ownership tab for more information on the TNGX short interest.
TNGX Technical Analysis
TNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TNGX. No worries on liquidiy or solvency for TNGX as it has an excellent financial health rating, but there are worries on the profitability.
TNGX Financial Highlights
Over the last trailing twelve months TNGX reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS decreased by -10% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.17% | ||
| ROE | -65.31% | ||
| Debt/Equity | 0 |
TNGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to TNGX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -17.38% and a revenue growth -36.08% for TNGX